research 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
Search
for
Sort by
Research
210-240 / 1000+ results 
research Efficacy, Safety, and Real-World Aspects of Janus Kinase Inhibitors to Treat Patients With Alopecia Areata
Janus kinase inhibitors are effective and safe for treating alopecia areata.
research Determination of 13 janus kinase inhibitors in anti-alopecia cosmetics by ultra-high performance liquid chromatography-tandem triple quadrupole composite linear ion trap mass spectrometry
A new method accurately detects illegal JAK inhibitors in hair loss cosmetics.
research The JAK/STAT signaling pathway: from bench to clinic
The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
research JAK Inhibitors for Treatment of Alopecia Areata
JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
research JAK inhibitors and alopecia areata
JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.
research Treatment of pediatric alopecia areata: A systematic review
Topical corticosteroids are the best initial treatment for children's alopecia areata.
research Tofacitinib for the treatment of alopecia areata in preadolescent children
Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
research New drugs under investigation for the treatment of alopecias
New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
research Treatment of severe alopecia areata with baricitinib
Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
research Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes
A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
research Shared Decision-Making, Therapeutic Choice, and Decisional Regret in Patients With Alopecia Areata
Patients with alopecia areata feel less regret about treatment decisions when they are involved in the decision-making process.
research The role of oclacitinib in the management of ischaemic dermatopathy in four dogs
Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.
research Upadacitinib for Successful Treatment of Alopecia Universalis in a Child: A Case Report and Literature Review
Upadacitinib effectively treated severe hair loss in a child.
research Rethinking the classification of alopecia areata
The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
research Innovative strategies for the discovery of new drugs against alopecia areata: taking aim at the immune system
New, effective treatments for alopecia areata require innovative approaches targeting the immune system.
research Upadacitinib in concurrent Crohn's disease, atopic dermatitis and alopecia areata: A case report
Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.
research A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
research Alopecia areata – Current understanding and management
Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.
research An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
research Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
research Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report
Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
research Single‐cell transcriptomics reveals a senescence‐associated IL ‐6/ CCR6 axis driving radiodermatitis
Blocking certain immune signals can reduce skin damage from radiation therapy.
research Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: A case report and review of the literature
Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
research Alopecia areata following COVID-19 vaccine: a systematic review
Alopecia areata after COVID-19 vaccination is rare but important to recognize for timely treatment.
research Emerging role of baricitinib in dermatology practice: All we need to know!
Baricitinib effectively treats certain skin conditions but may have serious side effects.
research Folliculitis decalvans responsive to tofacitinib: A case series
Tofacitinib may effectively treat folliculitis decalvans.
research What is behind the ‘swarm of bees’ in alopecia areata
Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.
research Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: A case report
Upadacitinib successfully treated a child's severe skin and hair loss issues.
research Acne exacerbation after tofacitinib treatment for alopecia areata
Tofacitinib treatment for hair loss may worsen acne.